VistaGen Therapeutics
VTGN
22 hedge funds and large institutions have $3.23M invested in VistaGen Therapeutics in 2018 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 1 reducing their positions, and 5 closing their positions.
500% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 1
60% more capital invested
Capital invested by funds: $2.02M → $3.23M (+$1.22M)
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
10% more funds holding
Funds holding: 20 → 22 (+2)
0.03% more ownership
Funds ownership: 0.32% → 0.35% (+0.03%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$144K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$124K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$84K |
| 4 |
RC
RBF Capital
San Francisco,
California
|
+$29K |
| 5 |
DADC
D.A. Davidson & Co
Great Falls,
Montana
|
+$26.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$133K |
| 2 |
CA
Corrado Advisors
Ramsey,
New Jersey
|
-$24.3K |
| 3 |
BC
Bartlett & Co
Cincinnati,
Ohio
|
-$14K |
| 4 |
BCWM
Bartlett & Co Wealth Management
Cincinnati,
Ohio
|
-$13.9K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$12K |
VTGN Hedge Fund Activity: Q2 2018 in Review
22 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q2 2018, worth a combined $3.23M — up 60% from $2.02M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new VTGN positions and 5 closed out — a net gain of 2 holders — while 6 added to existing stakes and 1 trimmed.
The largest buyer was Sphera Funds Management, adding an estimated $144K. The largest seller was Sabby Management, exiting entirely with an estimated $133K sold.
- 22 institutional investors held VistaGen Therapeutics (VTGN) as of Q2 2018, up from 20 in Q1 2018.
- Funds reported $3.23M of VistaGen Therapeutics stock for Q2 2018, up 60% quarter-over-quarter.
- 7 funds opened new VistaGen Therapeutics positions in Q2 2018 and 5 closed out, a net change of +2 holders.
- The largest VistaGen Therapeutics buyer in Q2 2018 was Sphera Funds Management, an estimated $144K added.
- The largest VistaGen Therapeutics seller in Q2 2018 was Sabby Management, an estimated $133K sold.
Based on aggregated 13F filings for Q2 2018.